PRISM

Paige Delivers the Power of Foundation Model Technology to Revolutionize Pharmaceutical & Life Science AI Development

Retrieved on: 
木曜日, 5月 30, 2024
Research, Pharmaceutical, Oncology, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, Probability, Organization, Privacy, Foundation models, Senior, AI, Pathology, Drug discovery, PRISM, Artificial intelligence, Acceleration, Pharmaceutical industry

As part of this offering, customers will gain access to pre-trained models such as advanced versions of Virchow, the 1.5 million-slide scale model introduced last year--the world’s largest image-based AI model to fight cancer—and the newly released PRISM Foundation Model, a multi-modal slide-level model which offers added reporting and generative capabilities. The deep specificity and accuracy of PRISM allows AI teams to tap into analytical data related to advanced multi-tissue cancer and rare cancer detection, rare biomarker identification, cellular subtyping, spatial biology, and therapy response prediction that they could not have accessed with previous technology. Paige will also provide access to a dedicated AI support and services team to ensure partners can access the full power of Paige’s Foundation model quickly and accelerate their internal R&D timelines.

Key Points: 
  • The result could be a dramatic acceleration of innovation in precision oncology, improving the way cancer is diagnosed and treated around the world.
  • Paige will also provide access to a dedicated AI support and services team to ensure partners can access the full power of Paige’s Foundation model quickly and accelerate their internal R&D timelines.
  • “Paige’s Foundation Models are powerful pre-trained technologies that now put AI capabilities at the fingertips of pharmaceutical companies, representing a significant step forward for drug discovery and development,” said Razik Yousfi, Senior Vice President of Technology at Paige.
  • "The new service line powered by our Foundation Models pushes us one step closer to making this ambition a reality.

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

Retrieved on: 
水曜日, 5月 29, 2024
Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Microsoft, Spectral, Science, Mass spectrometry, Doctor of Philosophy, Conceptual model, Collection, Chemistry, Azure, EVP, Language, AI, Drug discovery, PRISM, Data science, Nature, Business development, Management

Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM, trained on the world’s largest collection of experimental mass spectra.

Key Points: 
  • Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new collaboration with Microsoft and released details on their work creating their Foundation Model, called PRISM, trained on the world’s largest collection of experimental mass spectra.
  • The collaboration with Microsoft includes access to compute resources needed to power Enveda’s novel drug discovery platform.
  • Enveda will use Microsoft Azure to scale its generative AI models, including the newly revealed model, PRISM.
  • “By combining Microsoft Azure infrastructure with Enveda's data, expertise, and vision, an entirely new realm of chemistry can be explored to identify new medicines.”

Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

Retrieved on: 
木曜日, 5月 23, 2024
MSD, Pembrolizumab, Merck & Co., Patient, Oxidative stress, TPS, Trastuzumab, Science, HER2, Proteostasis, Tumor microenvironment, FDA, Endometrial cancer, Safety, Breast cancer, ADC, Senior, Headquarters, LEAP, Research, Deep, Cancer, Drug discovery, ASCO, Merck, PRISM, Society, Apoptosis, Hepatocellular carcinoma, Differentiable function, Inflammation, Hypoxia, Annual general meeting, Pharmaceutical industry

TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.

Key Points: 
  • TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois from May 31 to June 4.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains with the aim of contributing to the cure of cancers.
  • (1) KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon

Retrieved on: 
火曜日, 5月 21, 2024
Disease, Patient, COVID-19, Food, European Medicines Agency, Interview, CTCL, FDA, Drug development, Psoriasis, Dermatology, Cutaneous T-cell lymphoma, EMA, Journal, FLASH, PRISM, Therapy, Ricin, NIH, Pharmaceutical industry

Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer.

Key Points: 
  • Soligenix has recently achieved success in its first Phase 3 clinical trial of HyBryte™ (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer.
  • The trial showed statistical significance in its primary endpoint, and a second confirmatory Phase 3 study is set to commence in 2024.
  • The open-label study, involving nine patients, showed significant improvements in CTCL lesions, confirming the efficacy seen in the Phase 3 FLASH trial.
  • "We will be enrolling the first patients in our 18-week Phase 3 placebo-controlled study evaluating HyBryte™ in CTCL across the US and Europe.

SURJET awarded ARGUS Platinum Rating

Retrieved on: 
金曜日, 5月 24, 2024
Luxury, Other Transport, Air, Transport, Specialty, Other Travel, Transportation, Logistics, Supply Chain Management, Retail, Travel, ARGUS, Emergency, Safety management system, Aviation, Pleasure, Aircraft, Certification, CHEQ, Business Aviation, Culture, International, PRISM, Communication, Multimedia, SMS

ARGUS International honors SURJET as an ARGUS Platinum Operator, which places them in the upper five percent of over 1,000 U.S. based charter operators.

Key Points: 
  • ARGUS International honors SURJET as an ARGUS Platinum Operator, which places them in the upper five percent of over 1,000 U.S. based charter operators.
  • The Platinum rating is the highest level in the ARGUS audit standard and is awarded only to those air charter operators who have demonstrated successful implementation of industry best safety practices regarding their operations and maintenance.
  • View the full release here: https://www.businesswire.com/news/home/20240510173348/en/
    "The SURJET team was a pleasure to work with,” states Ed Wandall , ARGUS International Vice President Business Aviation.
  • Committed to the safety and security of its clients, SURJET garners several prestigious safety accreditations, including Platinum rating by ARG/US and Industry Audit Standard registration from the Air Charter Safety Foundation.

Erste Asset Management Selects Clearwater Analytics to Help Support Business Growth

Retrieved on: 
火曜日, 5月 14, 2024
Clearwater Analytics, Partnership, Software as a service, Data management, Erste Group, Accounting, PRISM, RFP

BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ -- Clearwater Analytics (NYSE: CWAN), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients. Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.

Key Points: 
  • Clearwater Will Aggregate Multi-Asset Client Investment Data, Help Increase Asset Flows and Strengthen Client Service
    BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ -- Clearwater Analytics (NYSE: CWAN), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients.
  • Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.
  • By leveraging the Clearwater PRISM platform , Erste AM will be able to provide highly customized digital client experiences.
  • "We are dedicated to surpassing customer expectations and providing exceptional client reporting across all channels," said Winfried Buchbauer, COO and Board Member of Erste Asset Management.

Erste Asset Management Selects Clearwater Analytics to Help Support Business Growth

Retrieved on: 
火曜日, 5月 14, 2024
Clearwater Analytics, Partnership, Software as a service, Data management, Erste Group, Accounting, PRISM, RFP

BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ -- Clearwater Analytics (NYSE: CWAN), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients. Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.

Key Points: 
  • Clearwater Will Aggregate Multi-Asset Client Investment Data, Help Increase Asset Flows and Strengthen Client Service
    BOISE, Idaho and VIENNA, May 14, 2024 /PRNewswire/ -- Clearwater Analytics (NYSE: CWAN), a leading worldwide provider of SaaS-based investment management, accounting, reporting, and analytics solutions, today announced that Erste Asset Management GmbH, part of Erste Group Bank AG, has joined its community of European buy-side clients.
  • Erste Asset Management (Erste AM) is one of the leading asset managers in Central and Eastern Europe managing €81.4 billion in assets for a broad client base including pension plans.
  • By leveraging the Clearwater PRISM platform , Erste AM will be able to provide highly customized digital client experiences.
  • "We are dedicated to surpassing customer expectations and providing exceptional client reporting across all channels," said Winfried Buchbauer, COO and Board Member of Erste Asset Management.

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
木曜日, 5月 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace

Retrieved on: 
火曜日, 5月 7, 2024
Economics, Health, Immunotherapy, Interview, PRISM, Growth, OCX

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth.

Key Points: 
  • NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation’s Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth.
  • Oncocyte (Nasdaq: OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets.
  • “Building out commercial teams can be incredibly expensive, and it doesn’t always return shareholder value.
  • Our strategy involves entering partnerships with leading providers that have established commercial channels, as we work to commercialize our distributable kitted product,” states Mr. Riggs.

Everstream Analytics Appoints Supply Chain SaaS Visionary Paige Cox as Chief Product Officer to Lead the Next Stage of Innovation

Retrieved on: 
月曜日, 5月 6, 2024
Professional Services, Technology, Transport, Logistics, Supply Chain Management, Software, Other Transport, Dark, RET, Demand, Organization, Woman, Risk, AI, EVP, Risk management, Head, United States Marine Corps, Software as a service, Intelligence, Entrepreneurship, SVP, Trust, PRISM, Supply chain, Gartner, Embrace, Retail

Gartner Supply Chain Symposium – Everstream Analytics , the global supply chain insights and risk analytics company, today announced the executive appointment of Paige Cox, formerly an Everstream Executive Advisory Board Member, to Chief Product Officer.

Key Points: 
  • Gartner Supply Chain Symposium – Everstream Analytics , the global supply chain insights and risk analytics company, today announced the executive appointment of Paige Cox, formerly an Everstream Executive Advisory Board Member, to Chief Product Officer.
  • In her new role, Paige will utilize her extensive supply chain background to scale innovation for mass market success at Everstream.
  • In 2023 and 2022, Supply Chain Digital recognized Paige as one of the Top 100 Women in Supply Chain; she was also a 2023 and 2022 award recipient of “Pros to Know” and “Women in Supply Chain” by Supply & Demand Chain Executive.
  • “Everstream’s powerful platform capabilities signals its market making potential,” said Paige Cox, Chief Product Officer, Everstream.